Markets Leerink Partners analyst Marc Goodman maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) on April 26. The company’s shares closed last Wednesday at $59.74, close to its 52-week low of $50.05. According to TipRanks.com, Goodman is a 3-star analyst with an average return of 3.2% and a 47.7% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Intra-Cellular Therapies, and Satsuma Pharmaceuticals. Currently, the analyst consensus on Axsome Therapeutics is a Strong Buy with an average price target of $144.00, representing a 136.7% upside. In a report issued on April 26, Mizuho Securities also maintained a Buy rating on the stock with a $118.00 price target.